Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-α signaling complex

Abstract

We have previously demonstrated that the responsiveness of multiple myeloma (MM) cells to interferon-alpha (IFN-α) stimulation is variable, with an atypical growth response displayed by some cells. Here we report the ability of IFN-α to induce tyrosine phosphorylation of a 180 kDa band in the KAS-6/1 MM cell line, which is growth responsive to IFN-α. Further characterization demonstrated that this band corresponds to ErbB3. To our knowledge, this is the first report of ErbB3 expression in a cell type of the hematopoietic lineage. Although ErbB receptors have been shown to crosscommunicate with various other receptors, our results show for the first time that the IFN-α receptor can crosscommunicate with ErbB3. To address the significance of these observations, we transfected ErbB3-negative DP-6 MM cells with ErbB3 and used siRNA to silence ErbB3 in the KAS-6/1 cell line. Although IFN-α transactivated ErbB3 in the DP-6 transfectants, it did not confer growth responsiveness to IFN-α. Interestingly, silencing ErbB3 expression in the KAS-6/1 cells decreased the overall growth response to IFN-α and to interleukin-6. These results suggest that ErbB3 expression alone does not uniquely confer IFN-α growth responsiveness, but instead may amplify proliferation rates in MM cells that have acquired atypical expression of this receptor.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP and Kraus MH . (1995). Oncogene, 10, 1813–1821.

  • Arora T, Floyd-Smith G, Espy MJ and Jelinek DF . (1999). J. Immunol., 162, 3289–3297.

  • Blade J, Lopez-Guillermo A, Tassies D, Montserrat E and Rozman C . (1991). Br. J. Haematol., 79, 523–525.

  • Bregman MD and Sipes NJ . (1986). Int. J. Cell Cloning, 4, 224–236.

  • Brenning G, Ahre A and Nilsson K . (1985). Scand. J. Haematol., 35, 543–549.

  • Fiddes RJ, Campbell DH, Janes PW, Sivertsen SP, Sasaki H, Wallasch C and Daly RJ . (1998). J. Biol. Chem., 273, 7717–7724.

  • French JD, Tschumper RC and Jelinek DF . (2002). Leukemia, 16, 1189–1196.

  • Hill SM . (1998). Anat. Rec., 253, 42–48.

  • Jelinek DF, Aagaard-Tillery KM, Arendt BK, Arora T, Tschumper RC and Westendorf JJ . (1997). J. Clin. Invest., 99, 447–456.

  • Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R and Klein B . (1991). J. Immunol., 147, 4402–4407.

  • Kraus MH, Issing W, Miki T, Popescu NC and Aaronson SA . (1989). Proc. Natl. Acad. Sci., 86, 9193–9197.

  • Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ and Hurst HC . (1992). Br. J. Cancer, 66, 1116–1121.

  • McManus MJ, Boerner JL, Danielson AJ, Wang Z, Matsumura F and Maihle NJ . (2000). J. Biol. Chem., 275, 35328–35334.

  • Olayioye MA, Neve RM, Lane HA and Hynes NE . (2000). Embo J., 19, 3159–3167.

  • Pestka S . (1997). Semin. Oncol., 24, S9-18–S9-40.

  • Qiu Y, Ravi L and Kung HJ . (1998). Nature, 393, 83–85.

  • Salmon SE, Beckord J, Pugh RP, Barlogie B and Crowley J . (1991). Semin. Oncol., 18, 33–36.

  • Sawamura M, Murayama K, Ui G, Matsushima T, Tamura J, Murakami H, Naruse T and Tsuchiya J . (1992). Br. J. Haematol., 82, 631.

  • Soltoff SP, Carraway KL, Prigent SA, Gullick WG and Cantley LC . (1994). Mol. Cell Biol., 14, 3550–3558.

  • Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconiz JM, Edgehouse NL, Pretlow TP, Bodner DR and Kurch ED . (1994). Cancer Res., 54, 6049–6052.

  • Walters DK and Jelinek DF . (2002). Antisense Nucleic Acid Drug Dev., 12, 411–418.

  • Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA and Jelinek DF . (1996). Leukemia, 10, 866–876.

  • Yamauchi T, Ueki K, Tobe K, Tamemoto H, Sekine N, Wada M, Honjo M, Takahashi M, Takahashi T, Hirai H, Tushima T, Akanuma Y, Fujita T, Komuro I, Yazaki Y and Kadowaki T . (1997). Nature, 390, 91–96.

Download references

Acknowledgements

We thank Drs Nita Maihle and Hakjoo Lee for helpful discussions and Dr Anne J Novak for reading the manuscript. We also acknowledge the technical expertise of Renee C Tschumper. This work was supported by National Institutes of Health NCI Grants CA62242 and CA62228 (DFJ).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Diane F Jelinek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walters, D., French, J., Arendt, B. et al. Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-α signaling complex. Oncogene 22, 3598–3607 (2003). https://doi.org/10.1038/sj.onc.1206512

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206512

Keywords

This article is cited by

Search

Quick links